Immunic (IMUX) News Today → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free IMUX Stock Alerts $1.24 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineImmunic (NASDAQ:IMUX) Rating Increased to Hold at StockNews.comamericanbankingnews.com - April 21 at 1:34 AMImmunic (NASDAQ:IMUX) Upgraded by StockNews.com to "Hold"marketbeat.com - April 19 at 11:04 PMImmunic, Inc. (IMUX)finance.yahoo.com - April 19 at 3:55 PMAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)markets.businessinsider.com - April 16 at 8:56 AMShort Interest in Immunic, Inc. (NASDAQ:IMUX) Rises By 22.7%marketbeat.com - April 15 at 10:28 PMImmunic Inc IMUXmorningstar.com - April 12 at 10:00 AMBrookline Capital starts Immunic at buy, cites MS drug candidatemsn.com - April 5 at 1:41 PMAnalysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Shockwave Medical (SWAV)markets.businessinsider.com - April 5 at 8:41 AMImmunic (NASDAQ:IMUX) Research Coverage Started at Brookline Capital Managementmarketbeat.com - April 5 at 8:21 AMWith 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investorsfinance.yahoo.com - April 4 at 3:43 PMImmunic to Host MS R&D Day and Participate in Investor Conferences in Aprilfinance.yahoo.com - April 4 at 7:35 AMShort Interest in Immunic, Inc. (NASDAQ:IMUX) Expands By 11.3%marketbeat.com - April 1 at 8:36 PMImmunic (NASDAQ:IMUX) Downgraded to "Sell" at StockNews.commarketbeat.com - March 29 at 11:14 PMImmunic Gets Allowance for Vidofludimus Calcium Patent Applicationmarketwatch.com - March 20 at 8:45 PMImmunic granted patent for specific polymorph of vidofludimus calcium in USproactiveinvestors.com - March 20 at 8:36 AMImmunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United Statesprnewswire.com - March 20 at 6:30 AMShort Interest in Immunic, Inc. (NASDAQ:IMUX) Declines By 11.9%marketbeat.com - March 18 at 5:15 PMImmunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Monthproactiveinvestors.com - March 18 at 1:05 PMImmunic (NASDAQ:IMUX) Upgraded to Hold at StockNews.commarketbeat.com - March 11 at 11:15 PMImmunic to Participate in Investor and Scientific Conferences in Marchprnewswire.com - March 7 at 6:30 AMImmunic to present data for lead asset vidofludimus calcium from Phase 2 MS and COVID-19 trialsproactiveinvestors.com - February 29 at 8:42 AMImmunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024prnewswire.com - February 29 at 6:30 AMHold Rating on Immunic: Balancing Long-Term Potential Against Short-Term Uncertaintiesmarkets.businessinsider.com - February 26 at 4:40 AMImmunic Inc (IMUX) Reports Year-End 2023 Financial Resultsfinance.yahoo.com - February 23 at 11:14 PMImmunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 23 at 1:14 PMBuy Rating Affirmed for Immunic Amid Progress in IMU-838 Trials and Extended Financial Runwaymarkets.businessinsider.com - February 22 at 10:12 PMImmunic expects financial stability through 2025 as MS clinical programs advanceproactiveinvestors.com - February 22 at 9:46 AMImmunic reports successful 2023 and prepares for key 2025 milestonesproactiveinvestors.com - February 22 at 7:09 AMImmunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - February 22 at 7:09 AMImmunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Updateprnewswire.com - February 22 at 6:30 AMImmunic Stock (NASDAQ:IMUX) Dividends: History, Yield and Datesbenzinga.com - February 21 at 4:08 PMImmunic's Earnings Outlookbenzinga.com - February 21 at 4:08 PMImmunic (IMUX) to Release Earnings on Thursdaymarketbeat.com - February 16 at 9:53 AMImmunic's cutting-edge MS treatment approach: insights from CEO Dr Daniel Vittproactiveinvestors.com - February 15 at 10:31 AMImmunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Updatefinance.yahoo.com - February 15 at 8:46 AMImmunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Updateprnewswire.com - February 15 at 6:30 AMFY2023 Earnings Forecast for Immunic, Inc. (NASDAQ:IMUX) Issued By Leerink Partnrsmarketbeat.com - February 8 at 7:06 AMLeerink Partnrs Comments on Immunic, Inc.'s FY2028 Earnings (NASDAQ:IMUX)marketbeat.com - February 7 at 9:09 AMImmunic says $240M financing shows confidence in Phase 2 CALLIPER study as it targets unmet MS needsproactiveinvestors.com - February 1 at 2:59 PMImmunic to Participate in Investor and Scientific Conferences in Februaryfinance.yahoo.com - February 1 at 9:59 AMInvestors Await Jobs Data as US Futures Trend Lower in Friday's Premarketmsn.com - January 5 at 4:47 PMWhat's Going On With Immunic Stock?msn.com - January 5 at 4:47 PMImmunic announces private placement of up to $240 millionmsn.com - January 5 at 8:30 AMImmunic Shares Rise Premarket on Private-Placement Financingmarketwatch.com - January 5 at 8:30 AMImmunicto Privately Place Up To $240 Mln Of Shares; Stock Up In Pre-marketmarkets.businessinsider.com - January 5 at 8:30 AMImmunic, Inc. Announces Private Placement of up to $240 Millionfinance.yahoo.com - January 5 at 8:30 AMImmunic Highlights 2023 Accomplishments and Upcoming Milestonesfinance.yahoo.com - January 5 at 8:30 AMImmunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosisfinance.yahoo.com - November 21 at 8:25 AMAnalysts Offer Insights on Healthcare Companies: Trevena (TRVN) and Immunic (IMUX)markets.businessinsider.com - November 15 at 8:16 AMImmunic focusing on business development during Q4proactiveinvestors.com - November 14 at 10:13 AM Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… IMUX Media Mentions By Week IMUX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUX News Sentiment▼0.210.43▲Average Medical News Sentiment IMUX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUX Articles This Week▼31▲IMUX Articles Average Week Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Adagene News Societal CDMO News Coya Therapeutics News Citius Pharmaceuticals News Annovis Bio News InterCure News OptiNose News Cellectar Biosciences News Repare Therapeutics News Nuvectis Pharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMUX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressPentagon contract could send this $2 AI stock soaringBehind the MarketsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
